| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5676930 | BOEHRINGER INGELHEIM | Stabilized medicinal aerosol solution formulations |
Oct, 2014
(9 years ago) | |
| US5683677 | BOEHRINGER INGELHEIM | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US6739333 | BOEHRINGER INGELHEIM | Stainless steel canister for propellant-driven metering aerosols |
May, 2020
(3 years ago) | |
| US6983743 | BOEHRINGER INGELHEIM | Stainless steel canister for propellant-driven metering aerosols |
May, 2020
(3 years ago) | |
| US8474447 | BOEHRINGER INGELHEIM | Inhaler device |
Jan, 2030
(5 years from now) | |
Atrovent Hfa is owned by Boehringer Ingelheim.
Atrovent Hfa contains Ipratropium Bromide.
Atrovent Hfa has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Atrovent Hfa are:
- US5676930
- US5683677
- US6739333
- US6983743
Atrovent Hfa was authorised for market use on 27 November, 2004.
Atrovent Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Atrovent Hfa are possible to be released after 17 January, 2030.
Drugs and Companies using IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 27 November, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
More Information on Dosage
ATROVENT HFA family patents
